Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. [PDF]
Arthritis Res Ther, 2003 Mukherjee D, Topol EJ.
europepmc +1 more source
CompEx Asthma: is it time for a change in clinical trials? [PDF]
Eur Respir JWilkinson TMA, Akuthota P.
europepmc +1 more source
Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. [PDF]
Curr Control Trials Cardiovasc Med, 2001 Bhatt DL, Topol EJ.
europepmc +1 more source
Opportunities in Development of Patient-Centric and Decentralized Clinical Trials: Insights from Patients and Healthcare Professionals in Respiratory and Rare Diseases. [PDF]
Ther Innov Regul SciMinetti M +11 more
europepmc +1 more source
Miscues on the "lack of MEF2A mutations" in coronary artery disease. [PDF]
J Clin Invest, 2005 Wang Q, Rao S, Topol EJ.
europepmc +1 more source
Economics and quality of care for patients with acute coronary syndromes: the impending crisis. [PDF]
Clin Cardiol, 2002 Topol EJ.
europepmc +1 more source
Artificial Intelligence for Spirometry Quality Evaluation: A Systematic Review. [PDF]
Bioengineering (Basel)López-Canay J +6 more
europepmc +1 more source
Mikropropagacija bijele topole (Populus alba L.)
Šumarski list, 2008 Kultura je multiplicirana iz nodalnih segmenata i vrhova sterilnih izbojaka bijele topole (Populus alba L.) na osnovnoj podlozi: modificiranoj podlozi Woody Plant Medium (WPM; MS /Murashige i Skoog/ – makroelementi, WPM – mikroelementi i vitamini) uz dodatak 0,25 ili 0,5 mg/l BA (6-benziladenin).
openaire +1 more source
The primacy of clinical effectiveness for cost effectiveness analysis. [PDF]
Heart, 2003 Casserly IP, Topol EJ.
europepmc +1 more source